Chemoprevention of breast cancer

American Journal of Health-System Pharmacy

Volumn 65, Issue 23, 2008, Pages 2221-2228

  Thomsen, Annelise ^a   Kolesar, Jill M ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Antineoplastic agents; Breast neoplasms; Diagnosis; Genetics; Raloxifene; Tamoxifen; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; PLACEBO; RALOXIFENE; TAMOXIFEN;

BLADDER DISEASE; BONE DENSITY; BREAST BIOPSY; BREAST CANCER; BREAST SELF EXAMINATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CATARACT; CHOLESTEROL BLOOD LEVEL; DEEP VEIN THROMBOSIS; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DYSPAREUNIA; EARLY DIAGNOSIS; ENDOMETRIUM HYPERPLASIA; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; EXERCISE; FLU LIKE SYNDROME; GYNECOLOGIC DISEASE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LEG CRAMP; LIFESTYLE MODIFICATION; LOW FAT DIET; LUNG EMBOLISM; MAMMOGRAPHY; MUSCULOSKELETAL DISEASE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PERIPHERAL EDEMA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UTERUS CANCER; VAGINA BLEEDING; VASOMOTOR DISORDER; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 57149113187     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070663     Document Type: Review

References (28)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57:43-66.
2. Espey DK, Wu XC, Swan J et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer. 2007; 110:2119-52.
3. National Cancer Institute. A snapshot of breast cancer. Incidence and mortality rate trends. http://planning.cancer.gov/disease/Breast-Snapshot.pdf (accessed 2008 Sep 2).
4. Bevers TB, Armstrong DK, Arun B et al. Breast cancer risk reduction. J Natl Compr Canc Netw. 2007; 5:676-701.
5. Rodriquez E, Domchek SM.The prevention of hereditary breast cancer. Semin Oncol. 2007; 34:401-5.
6. Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81:1879-86.
7. Costantino JP, Gail MH, Pee D et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999; 91:1541-8.
8. Decarli A, Calza S, Masala G et al. Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition cohort. J Natl Cancer Inst. 2006; 98:1686-93.
9. Linos E, Willett WC. Diet and breast cancer risk reduction. J Natl Compr Canc Netw. 2007; 5:711-8.
10. Mahoney MC. Breast cancer risk reduction and counseling: lifestyle, chemoprevention, and surgery. J Natl Compr Canc Netw. 2007; 5:702-10.
11. Glass AG, Lacey JV Jr, Carreon JD et al. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007; 99:1152-61.
12. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2006: CD001877.
13. Fisher B, Costantino JP, Wickerham JL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Natl Cancer Inst. 1998; 90:1371-88.
14. Powles T, Eeles R, Ashley S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998; 352:98-101.
15. Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998; 352:93-7.
16. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996; 10:905-12.
17. Grese TA, Sluka JP, Bryant HU et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci U S A. 1997; 94:14105-10.
18. Brzozowski AM, Pike AC, Dauter Z et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997; 389:753-8.
19. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and anti-hormonal resistance in breast cancer. Clin Oncol. 2007; 25:5815-24.
20. Sporn MB, Dowsett SA, Mershon J et al. Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clin Ther. 2004; 26:830-40.
21. Bevers TB. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. Natl Compr Canc Netw. 2007; 5:719-24.
22. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999; 281:2189-97. [Erratum, JAMA. 1999; 282:2124.]
23. Siris E, Adachi JD, Lu Y et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporos Int. 2002; 13:907-13.
24. Martino S, Cauley JA, Barrett-Connor E et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Canc Inst. 2004; 96:1751-61.
25. Barrett-Connor E, Mosca IL, Collins P et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006; 355: 125-37.
26. Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Ralmdfene (STAR) P-2 trial. JAMA. 2006; 295:2727-41. [Erratum, JAMA. 2006; 296:2926.] [Erratum, JAMA. 2007; 298:973.]
27. Land SR, Wickerham DL, Costantino JP et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxden and Raloxifene (STAR) P-2 trial. JAMA. 2006; 295:2742-51. [Erratum, JAMA. 2007; 298:973.]
28. Heisey R, Pimlott N, Clemons M et al. Women's views on chemoprevention of breast cancer: qualitative study. Can Fam Physician. 2006; 52:624-5.